Related references
Note: Only part of the references are listed.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis
Guo-Ying Liu et al.
CANCER COMMUNICATIONS (2018)
Nasopharyngeal carcinoma incidence and mortality in China, 2013
Kuang-Rong Wei et al.
CHINESE JOURNAL OF CANCER (2017)
Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial
Ying Sun et al.
LANCET ONCOLOGY (2016)
Prognostic Value of Plasma Epstein-Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era
Wen-Hui Chen et al.
MEDICINE (2016)
Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis
Pierre Blanchard et al.
LANCET ONCOLOGY (2015)
Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522
K. Kian Ang et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Concurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous cell carcinomas of the head and neck (SCCHN): A systematic review
Madhusmita Behera et al.
ORAL ONCOLOGY (2014)
Concurrent Weekly Docetaxel Chemotherapy in Combination with Radiotherapy for Stage III and IVA-B Nasopharyngeal Carcinoma
Wei-Hong Wei et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2012)
Current understanding and management of nasopharyngeal carcinoma
Tomokazu Yoshizaki et al.
AURIS NASUS LARYNX (2012)
Impact of changing gross tumor volume delineation of intensity-modulated radiotherapy on the dose distribution and clinical treatment outcome after induction chemotherapy for the primary locoregionally advanced nasopharyngeal carcinoma
Zhan Yu et al.
Chinese Journal of Cancer (2012)
Concurrent Chemoradiotherapy vs Radiotherapy Alone in Stage II Nasopharyngeal Carcinoma: Phase III Randomized Trial
Qiu-Yan Chen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Randomized Phase II Trial of Concurrent Cisplatin-Radiotherapy With or Without Neoadjuvant Docetaxel and Cisplatin in Advanced Nasopharyngeal Carcinoma
Edwin P. Hui et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer
Edgardo Rivera et al.
CANCER (2008)
A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma
DTT Chua et al.
ORAL ONCOLOGY (2005)
Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC)
R Gervais et al.
ANNALS OF ONCOLOGY (2005)
Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma
JY Shao et al.
CANCER (2004)
Radiotherapy with concomitant weekly docetaxel for stages III/IV oropharynx carcinoma. Results of the 98-02 gortec phase II trial
G Calais et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Radiosensitization of colon cancer cell lines by docetaxel: Mechanisms of action
AL Dunne et al.
ONCOLOGY RESEARCH (2004)
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer
AA Forastiere et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Phase I study of weekly docetaxel infusion and concurrent radiation therapy for head and neck cancer
M Suzuki et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
